Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

By Reardon David   Desjardins Annick   Peters Katherine   Gururangan Sridharan   Sampson John   Rich Jeremy   McLendon Roger   Herndon James   Marcello Jennifer   Threatt Stevie   Friedman Allan   Vredenburgh James   Friedman Henry  

Journal of Neuro-Oncology, Vol. 103, Iss. 2, 2011-06 ,pp. : 371-379

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

By Rohrberg Kristoffer S.   Olesen René K.   Pfeiffer Per   Ladekarl Morten   Pappot Helle   Christensen Ib J.   Høyer-Hansen Gunilla   Sørensen Morten   Skov Birgit G.   Buysschaert Ian   Carmeliet Peter   Lassen Ulrik  

Acta Oncologica, Vol. 51, Iss. 2, 2012-02 ,pp. : 234-242

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

By Poulsen Hans Skovgaard   Grunnet Kirsten   Sorensen Morten   Olsen Preben   Hasselbalch Benedikte   Nelausen Knud   Kosteljanetz Michael   Lassen Ulrik  

Acta Oncologica, Vol. 48, Iss. 1, 2009-01 ,pp. : 52-58

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)

By Hamaguchi Tetsuya  

Gastric Cancer, Vol. 14, Iss. 3, 2011-08 ,pp. : 226-233

Springer Publishing Company

Access to resources Recommend Favorite